

Survival benefit and utilization disparities of lymph node dissection in clinically node-negative T2+ penile squamous cell carcinoma

A SEER database analysis

Hangcheng Fu*, Abigail George*, Uzoma Anele, Mohammed Said, Jamie Messer, Murali K. Ankem

Department of Urology, University of Louisville School of Medicine, Louisville, KY, United States
*Equal contributors

Cite as: Fu H, George A, Anele U, et al. Survival benefit and utilization disparities of lymph node dissection in clinically node-negative T2+ penile squamous cell carcinoma: A SEER database analysis. *Can Urol Assoc J* 2026;20(11):E442-8. <http://dx.doi.org/10.5489/cuaj.9588>

Published online July 20, 2026

Appendix available at cuaj.ca

ABSTRACT

INTRODUCTION: Penile squamous cell carcinoma (PSCC), although rare, presents significant morbidity. Current guidelines recommend lymph node dissection (LND) or lymph node biopsy on a risk-stratified basis for intermediate- or high-risk patients; however, survival benefits of LND in clinically node-negative patients need further exploration.

METHODS: Patients with T2+N0M0 PSCC were identified from the Surveillance, Epidemiology, and End Results (SEER) database (2004–2015). Inclusion required histologically confirmed squamous cell carcinoma localized to the penis. Patients with unavailable staging or unknown followup were excluded. Chi-squared tests, Kaplan-Meier survival curves, and multivariable Cox regression analyses assessed disease-specific survival (DSS).

RESULTS: A total of 825 patients were analyzed. The cohort predominantly included non-Hispanic White (65.2%) and Hispanic (22.3%) patients, with a median age of 69 years. Most patients were married (57.2%), while few received radiation (6.6%) or chemotherapy (3.5%). Only 23.5% underwent LND, with no significant variation across T stages. Median followup was 60 months. Chemotherapy use increased significantly with advancing T stage ($p=0.009$), whereas radiation did not. LND significantly improved DSS overall ($p<0.001$), specifically in T2 ($p=0.040$) and T3 stages ($p=0.002$). Multivariable analysis identified LND as an independent protective factor (hazard ratio [HR] 0.457, 95% confidence interval [CI] 0.328–0.711, $p<0.001$). Younger patients (<40 years) had higher LND rates (56%) compared to older patients (>70 years; 14.8%).

CONCLUSIONS: Despite National Comprehensive Cancer Network guidelines recommending LND for T2N0M0 PSCC, utilization remains low. Our findings highlight a survival advantage associated with regional LND, underscoring the need for enhanced urologist education to improve adherence and patient outcomes.

INTRODUCTION

Penile cancer is a rare malignancy in North America, with an incidence of less than one new case per 100 000 males.^{1,2} Although penile malignancies make up <1% of cancers in men in the U.S., rates are higher, at up to 4.4 out of 100 000 men, in developing countries.¹ The most significant prognostic factor is the extent of regional lymph node involvement.²

Inguinal lymph nodes are the first site of metastatic spread in penile carcinoma and thus represent the most significant predictors of survival; the five-year survival rate of penile cancer patients without inguinal node involvement is up to 85–100%, but as low as 15–45% in those with inguinal node metastasis.^{1,3}

Involvement of pelvic lymph nodes represents even more aggressive behavior, such that five-year survival in those patients drops below 15% and, in these men, delayed surgical intervention adversely affects survival.^{4,5} Inguinal lymph node staging is therefore critical when making the diagnosis, but is difficult, as 20–25% of clinically negative lymph nodes have micro-metastases.^{1,3}

While local tumor stage and grade are predictive of occult lymph node micro-metastasis with high reliability in the low- and high-risk groups, it is less reliable in the intermediate-risk group.⁶ Due to this tendency for early lymphatic metastasis, treatment of regional lymph nodes through surgical dissection is crucial for prognosis, but requires a delicate balance of

identifying clinically normal, but involved, nodes without overexposing patients to the complications of lymphadenectomy.

For penile cancer patients without palpable inguinal lymph nodes, The National Comprehensive Cancer Network (NCCN) guidelines recommend surveillance for low-risk (Tis, Ta, T1a) disease and imaging and staging with either inguinal lymph node dissection (ILND) or dynamic sentinel lymph node biopsy (DSLNB) in intermediate- or high-risk patients (T1b, T2 or higher).⁷ In clinically node-negative patients, prophylactic ILND has been shown to afford a higher five-year survival rate than in clinically node-positive patients.^{3,8}

Early resection of lymph node metastasis improves disease specific three-year survival of patients with positive lymph nodes from 35% with metastasis to 84% after resection;^{8,9} however, prophylactic ILND—while providing optimal survival in clinically node-negative patients—has a >80% overtreatment rate and carries its own risks, with a complication rate of up to 25%, including skin necrosis, wound infection, lymphedema, seroma, lymphocele, and deep vein thrombosis (DVT), and is associated with substantial physical and psychological impact on patients.^{1,5,10}

Bevan-Thomas et al suggest prophylactic and therapeutic ILND confer an acceptable morbidity risk, considering the potential therapeutic benefit, and are associated with a lower incidence of complications than palliative ILND.¹¹ Although LND is the cornerstone of staging and management of penile cancer, only 19–37% of patients with high-grade or invasive penile cancer in the U.S. receive lymphadenectomy.⁸

Despite the past study emphasizing the importance of LND in staging penile cancer, no large cohort study focused on the survival benefit of LND in clinical lymph node-negative patients. In this study, using the Surveillance, Epidemiology, and End Results (SEER) database, we aimed to identify survival benefit and utilization disparities of LND in clinically node-negative T2+ penile squamous cell carcinoma (PSCC).

METHODS

The study received exemption from the institutional review board (IRB Number: 25.0389). Data were obtained from the SEER database's 18 registries using SEER*Stat software (version 8.4.2, seer.cancer.gov/seerstat). Patients diagnosed between 2004 and 2015 with PSCC were identified. Inclusion criteria were 1) primary penile cancer with codes including prepuce, glans penis, body of penis, overlapping lesion of penis, and penis not otherwise specified

(NOS); 2) histologically confirmed squamous cell carcinoma; and 3) pathologic stage T2, T3, or T4 with N0 and M0 status. Exclusion criteria included any nodal (N+) or metastatic (M+) disease, T1 tumors, missing Tumor-Node-Metastasis (TNM) stage information, or unknown survival times. From an initial cohort of 5356 penile cancer cases, 825 patients met inclusion criteria for analysis.

The primary outcome was disease-specific survival (DSS), calculated from the date of diagnosis to death specifically attributed to penile cancer. Additional clinical variables analyzed included age, race/ethnicity, marital status, tumor grade, radiation therapy, chemotherapy, LND status, and T stage.

Differences between groups were assessed using the Chi-squared test. Kaplan-Meier survival curves were generated and compared using the log-rank test. Univariate and multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) and evaluate the impact of clinicopathologic factors on DSS. Statistical analyses were performed with MedCalc software (version 18.2.1, Mariakerke, Belgium), and statistical significance was set at a two-sided p-value of <0.05.

RESULTS

As previously described, 825 patients were selected from a total of 5356 penile cancer patients identified in the SEER database from 2004–2015. The median followup for the entire cohort was 60 months. Figure 1 illustrates trends over time in LND. There was a modest increase in the proportion of patients undergoing LND




Figure 1. Trend in the proportion of clinically node-negative pT2+ penile squamous cell carcinoma patients undergoing lymph node dissection (LND) from 2004–2015.

Table 1. Patient demographics and diagnosis of patients with T2+NOM0 penile squamous cell carcinoma

Variables	All patients
All	825
Race	
Non-Hispanic White	539 (65.3%)
Non-Hispanic Black	64 (7.8%)
Hispanic (all races)	183 (22.2%)
Non-Hispanic Asian or Pacific Islander	34 (4.1%)
Non-Hispanic American Indian/Alaska Native	5(0.6%)
Age at diagnosis ^a	
Mean	67.48±13.2
Median (25–75%)	69 (58–78)
Marital status	
Married	474 (57.5%)
Single (never married)	145 (17.6%)
Widowed or divorced	161 (19.5%)
Unknown	45 (5.5%)
Grade	
Well-differentiated; grade I	184(22.3%)
Moderately differentiated; grade II	414 (50.2%)
Poorly differentiated; grade III	176 (21.3%)
Undifferentiated; anaplastic; grade IV	5 (0.6%)
Unknown	46 (5.6%)
Radiation	
Without	773 (93.7%)
With	52 (6.3%)
Chemotherapy	
Without	796 (96.5%)
With	29 (3.5%)
Lymph node dissection	
Without	630 (76.5%)
With	195 (23.5%)
T stage	
T2	503 (61.0%)
T3	287 (34.8%)
T4	35 (4.2%)

^aCalculated as a continuous variable.

(from 17% in 2004 to 31% in 2015). Nevertheless, the majority of patients did not undergo LND or sampling.

Patient characteristics by treatment

Table 1 summarizes the demographics and clinical characteristics of the T2+NOM0 cohort. Among these patients, 539 (65.3%) were non-Hispanic White, 64 (7.8%) were non-Hispanic Black, and 183 (22.2%) were Hispanic. The median age at diagnosis was 69 years. A majority (57.5%) were married at the time of diagnosis, while 17.7% had never married, and 19.6% were widowed. Tumor grading showed 22.3% as grade 1, 50.2% as grade 2, 21.3% as grade 3, and 0.6% as grade 4. Radiation therapy was administered to 6.3% of patients, while chemotherapy was administered to only 3.5%. Overall, 195 patients (23.5%) underwent LND or biopsy, while the remaining patients did not. By T stage, 503 (61.0%) were T2, 287 (34.8%) were T3, and 35 (4.2%) were T4.

As indicated in Supplementary Table 1 (available at cuaj.ca), there were no statistically significant differences in LND rates across T stages (22.7% for T2, 25.4% for T3, and 22.9% for T4). Similarly, radiotherapy rates did not differ significantly across T stages (6.4% for T2, 6.3% for T3, and 5.7% for T4); however, higher T stages correlated with increased chemotherapy use (2.4% for T2, 4.5% for T3, and 11.4% for T4; $p=0.009$).

Correlation between clinical characteristics and DSS in pT2+NOM0 penile cancer

Kaplan-Meier survival analysis (Figure 2) demonstrated significantly improved DSS for patients undergoing LND compared to those who did not (five-year median survival 82.0% vs. 72.2%, $p<0.001$). Subgroup analysis showed similar survival benefits for patients with T2 (five-year median survival 80.2% vs. 74.3%, $p=0.040$) and T3 (five-year median survival 85.5% vs. 69.6%, $p=0.002$) disease, but no significant difference in patients with T4 disease.

Multivariate Cox regression analysis confirmed that LND (HR 0.457, 95% confidence interval [CI] 0.310–0.674, $p<0.001$) and tumor grade significantly impacted DSS (Table 2). Compared to grade 1 tumors, grade 2 (HR 2.203, $p<0.001$), grade 3 (HR 2.386, $p<0.001$), and grade 4 (HR 4.602, $p=0.012$) tumors were associated with poorer survival.

The disparity of pT2+NOM0 patients who underwent LND

Table 3 highlights disparities in the use of LND. Although statistically non-significant, only 21.2% of the Non-

Hispanic White patients underwent LND, while 31.1% of the Hispanic patients underwent LND ($p=0.056$). Similarly, only 15% of patients with household incomes less than \$35 000 underwent LND compared to 23.8% of higher-income patients. Patients who were separated, widowed, or divorced were less likely to undergo LND (14.3%, 15.1%, and 21.3%, respectively). No non-Hispanic American Indian/Alaska Native patients underwent LND, while 31% of Hispanic patients did. Rural vs. urban residence did not influence LND utilization. Age was the strongest predictor of LND: 56% of patients under 40 underwent the procedure compared to only 14.8% of patients older than 70 years ($p<0.001$).

DISCUSSION

In this study, using a large population dataset, we demonstrated that patients with clinically node-negative T2+ PSCC who underwent LND showed significant DSS benefits compared to those who did not. Older age was associated with a reduced likelihood of receiving LND.

Lymph node involvement affects disease prognosis more than primary tumor characteristics and early identification and resection are imperative to patient survival;^{2,10,12} however, despite NCCN guidelines advocating for LND or DSLNB in intermediate- or high-risk patients, historical data shows these procedures have been underperformed.^{8,13}

Correa et al reported an increase in the rate of ILND from 23.3% to 33.6% over a decade (2004–2014) in patients for whom ILND was absolutely indicated per NCCN guidelines, with an overall LND rate of 27.2%.^{13,14} Consistent with this finding, our analysis of a national dataset from 2004–2015 revealed that only 23.5% of patients with T2+N0M0 PSCC underwent LND. Possible explanations for this discrepancy include concerns regarding procedure-related morbidity, limited physician experience, and inadequate guideline awareness. Thus, enhancing patient and community provider education should be a priority.

Previous studies indicate LND significantly predicts improved overall survival in clinically node-positive patients, with evidence from Ma et al supporting prophylactic LND in clinically node-negative (cN0) patients as beneficial for long-term survival;^{3,8} however, few studies have specifically targeted clinical node-negative populations. Our results showed LND to be significantly associated with DSS benefits across the entire cohort ($p<0.001$), specifically within T2 ($p=0.040$) and T3 stages ($p=0.002$), and independently prognostic for improved survival (HR 0.457,




Figure 2. Kaplan-Meier curves comparing disease-specific survival (DSS) between patients with and without lymph node dissection (LND) among clinically node-negative penile squamous cell carcinoma (PSCC) patients. (A) All pT2+ patients (median followup: 60 months); (B) pT2 patients (median followup: 61 months); (C) pT3 patients (median followup: 58 months); and (D) pT4 patients (median followup: 65 months).

Table 2. Multivariable Cox regression analysis of the clinical variables and penile cancer disease-specific survival

Variables	HR (95% CI)	p
Chemotherapy (with vs. without ^a)	1.808 (0.832–3.926)	0.134
Radiation (with vs. without ^a)	1.005 (0.013–14.67)	0.958
Lymph node dissection (with vs. without ^a)	0.457 (0.310–0.674)	<0.001
TNM stage		
T3 vs. T2a	1.074 (0.790–1.460)	0.646
T4 vs. T2a	1.770 (0.957–3.271)	0.068
Tumor grade		
Grade 2 vs. grade 1 ^a	2.203 (1.432–3.387)	<0.001
Grade 3 vs. grade 1 ^a	2.386 (1.474–3.863)	<0.001
Grade 4 vs. grade 1 ^a	4.602 (1.388–15.256)	0.012
Unknown vs. grade 1 ^a	0.887 (0.364–2.159)	0.792

^aReference group. $p<0.05$ is considered statistically significant. CI: confidence interval; HR: hazard ratio.

Table 3. Association between LND and penile cancer patients' socioeconomic status in T2+NOMO penile squamous cell carcinoma

Variables	No LND	LND	p
Rural urban continuum status			0.440
Counties in metropolitan areas >1 million population	312	112	
Counties in metropolitan areas of 250 000 to 1 million population	153	37	
Counties in metropolitan areas of <250 000 population	52	12	
Non-metropolitan counties adjacent to a metropolitan area	63	19	
Non-metropolitan counties not adjacent to a metropolitan area	49	15	
Unknown/missing/no match (Alaska or Hawaii - entire state)	1	0	
Race			0.056
Hispanic (all races)	126	57	
Non-Hispanic American Indian/Alaska Native	5	0	
Non-Hispanic Asian or Pacific Islander	26	8	
Non-Hispanic Black	48	16	
Non-Hispanic White	425	114	

p<0.05 is considered statistically significant, χ^2 test for categorical variables. LND: lymph node dissection.

95% CI 0.328–0.711, $p<0.001$), strongly supporting LND's survival advantages.

The two prevalent ILND approaches include open modified (MILD) and superficial (SILD) techniques, although a minimally invasive approach via robot-assisted video endoscopic inguinal lymphadenectomy is also performed at various centers. In patients with intermediate- and high- risk cN0 penile cancer, Ma et al suggest MILD as the optimal choice for staging given the low prevalence of DSLNB capacity and the complications associated with radical ILND;³ however, SILD has been shown to provide better oncologic clearance, with no groin recurrences, but significantly a higher complication rate.¹⁵

It has also been suggested that removed lymph node count and density play a role in predicting DSS rate after lymphadenectomy.¹⁰ Li et al found that in patients with pN0 penile cancer, the removal of at least 16 lymph nodes was associated with significantly longer DSS rates.¹⁰

Robot-assisted video endoscopic ILND, increasingly adopted by various centers, is a feasible tech-

Table 3 (cont'd). Association between LND and penile cancer patients' socioeconomic status in T2+NOMO penile squamous cell carcinoma

Variables	No LND	LND	p
Median household income inflation-adjusted to 2021			0.924
\$35 000–39 999	19	7	
\$40 000–44 999	31	7	
\$45 000–49 999	47	14	
\$50 000–54 999	40	8	
\$55 000–59 999	67	22	
\$60 000–64 999	76	24	
\$65 000–69 999	94	36	
\$70 000–\$74 999	64	19	
\$75 000+	181	56	
<\$35 000	11	2	
Marital status at diagnosis			0.133
Married (including common law)	355	119	
Single (never married)	106	39	
Divorced	59	16	
Widowed	73	13	
Others	37	8	
Age			<0.001
<40	11	14	
40–70	281	122	
>70	338	59	

p<0.05 is considered statistically significant, χ^2 test for categorical variables. LND: lymph node dissection.

nique that yields similar lymph node counts as an open approach, as well as reduced hospital stays and lower wound-associated complications.^{16–19} Sentinel-guided lymphadenectomy is also an alternative to traditional LND, with recent literature describing new marking techniques that do not require nuclear medicine infrastructure, such as the combination of indocyanine green (ICG) and superparamagnetic iron oxide nanoparticles (SPION), which thus have more generalized applicability to routine clinical practice.

Michalik et al performed a pilot study on the use of ICG and SPIONs injected peritumorally. They found a 66% concordance between preoperative magnetic resonance imaging and magnetometer-guided sentinel

node biopsy, and 96% concordance between magnetometer-guided fluorescence imaging and sentinel node biopsy.²⁰ Our study included diverse LND and sampling techniques; however, due to the nature of the SEER database coding, LND techniques were not differentiated.

Using SEER database analyses similar to ours, Johnson et al found survival improvements associated with lymphadenectomy involving ≥ 8 nodes.¹⁴ Due to the nature of the database, the patients included in this study were treated in 17 centers over a 17-year timeframe, thus ranging various inguinal lymphadenectomy techniques. Therefore, Li et al performed a standardized study of patients with PSCC treated at a single institution over a 10-year time frame and observed the removal of at least 16 lymph nodes was associated with longer DSS rate in patients with pN0 penile cancer.¹⁰ Our findings echoed this, as shown in Supplementary Figure 1 (available at cuaj.ca). We demonstrated survival differences when comparing patients who had ≤ 5 lymph nodes removed vs. those with >5 ($p=0.049$); however, no incremental survival benefits were observed for patients with >5 nodes removed, highlighting the importance of surgical quality rather than merely node quantity.

Socioeconomic disparities were notable in our findings, with non-Hispanic White patients less likely to receive LND compared to Hispanic patients. Sharma et al previously noted higher penile cancer incidence among Hispanic and African American populations, with worse survival outcomes for African Americans.²¹ Our cohort analysis underscored age as the strongest predictor of undergoing LND. Younger age at diagnosis among Hispanic patients possibly explains their higher likelihood of receiving LND compared to non-Hispanic White patients (Supplementary Table 2; available at cuaj.ca). Patients with lower incomes and unmarried status were also less likely to undergo LND, underscoring the need for targeted education and intervention in these high-risk populations to potentially improve survival outcomes.

Limitations

While the SEER database allows examination that would not be possible outside of a multi-institutional trial, several limitations exist. SEER's geographical coverage does not comprehensively represent the U.S. population, and it lacks critical information, such as patient comorbidities or specific risk factors influencing treatment decisions. Additionally, retrospective analysis limitations restrict our ability to clearly differentiate survival benefits due to more accurate staging vs. actual

micrometastasis removal. Prospective studies remain necessary to validate and expand upon our findings regarding LND's therapeutic benefits in clinically node-negative PSCC patients.

CONCLUSIONS

In this population-based study, LND was significantly associated with improved DSS in patients with clinically node-negative T2+ PSCC. Our findings highlight the urgent need to address disparities in LND utilization and to promote guideline adherence to improve outcomes in this rare but aggressive malignancy.

This paper has been peer reviewed.

COMPETING INTERESTS: The authors have no relevant conflicts of interest to report.

REFERENCES

1. Zekan DS, Dahman A, Hajiran AJ, et al. Prognostic predictors of lymph node metastasis in penile cancer: A systematic review. *Int Braz J Urol* 2021;47:943-56. <https://doi.org/10.1590/s1677-5538.1bju.2020.0959>
2. Hakenberg OW, Dräger DL, Erbersdobler A, et al. The diagnosis and treatment of penile cancer. *Dtsch Arztebl Int* 2018;115:646-52. <https://doi.org/10.3238/arztebl.2018.0646>
3. Ma S, Zhao J, Liu Z, et al. Prophylactic inguinal lymphadenectomy for high-risk cN0 penile cancer: The optimal surgical timing. *Front Oncol* 2023;13:1069284. <https://doi.org/10.3389/fonc.2023.1069284>
4. Dorff TB, Ballas LK, Schuckman AK. Current management strategy for penile cancer and future directions. *Curr Oncol Rep* 2017;19:54. <https://doi.org/10.1007/s11912-017-0615-4>
5. O'Brien JS, Perera M, Manning T, et al. Penile cancer: Contemporary lymph node management. *J Urol* 2017;197:1387-95. <https://doi.org/10.1016/j.juro.2017.01.059>
6. Salsana E, Iborra I, Rubio J, et al. Prospective validation of the association of local tumor stage and grade as a predictive factor for occult lymph node micrometastasis in patients with penile carcinoma and clinically negative inguinal lymph nodes. *J Urol* 2001;165:1506-9. [https://doi.org/10.1016/S0022-5347\(05\)66337-9](https://doi.org/10.1016/S0022-5347(05)66337-9)
7. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Penile cancer (Version 1.2024). Available at: <https://www.nccn.org> (accessed May 28, 2026)
8. Azizi M, Chipollini J, Peyton CC, et al. Current controversies and developments on the role of lymphadenectomy for penile cancer. *Urol Oncol* 2019;37:201-8. <https://doi.org/10.1016/j.urolonc.2018.08.017>
9. Kroon BK, Horenblas S, Lant AP, et al. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. *J Urol* 2005;173:816-9. <https://doi.org/10.1097/01.ju.0000154565.37397.4d>
10. Li ZS, Yao K, Chen P, et al. Disease-specific survival after radical lymphadenectomy for penile cancer: Prediction by lymph node count and density. *Urol Oncol* 2014;32:893-900. <https://doi.org/10.1016/j.urolonc.2013.11.008>
11. Bevan-Thomas R, Slaton JW, Pettaway CA. Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: The M.D. Anderson Cancer Center experience. *J Urol* 2002;167:1638-42. [https://doi.org/10.1016/S0022-5347\(05\)65169-5](https://doi.org/10.1016/S0022-5347(05)65169-5)
12. Chadha J, Chahoud J, Spiess PE. An update on treatment of penile cancer. *Ther Adv Med Oncol* 2022;14:17588359221127254. <https://doi.org/10.1177/17588359221127254>
13. Correa AF, Handorf E, Joshi SS, et al. Differences in survival associated with performance of lymph node dissection in patients with invasive penile cancer: Results from the National Cancer Database. *J Urol* 2018;199:1238-44. <https://doi.org/10.1016/j.juro.2017.11.121>
14. Johnson TV, Hsiao W, Delman KA, et al. Extensive inguinal lymphadenectomy improves overall 5-year survival in penile cancer patients: Results from the Surveillance, Epidemiology, and End Results program. *Cancer* 2010;116:2960-6. <https://doi.org/10.1002/cncr.25091>
15. Bakshi GK, Pal M, Jain DK, et al. Surgical templates for inguinal lymph node dissection in cN0 penile cancer: A comparative study. *Urol Oncol* 2023;41:393.e9-16. <https://doi.org/10.1016/j.urolonc.2023.06.014>

16. Abdullatif VA, Davis J, Cavayero A, et al. Single-port robotic inguinal lymph node dissection for penile cancer. *Urology* 2022;161:153-6. <https://doi.org/10.1016/j.urology.2021.12.007>
17. Brouwer OR, Albersen M, Parnham A, et al. European Association of Urology-American Society of Clinical Oncology collaborative guideline on penile cancer: 2023 update. *Eur Urol* 2023;83:548-60. <https://doi.org/10.1016/j.eururo.2023.02.027>
18. Singh A, Jaipuria J, Goel A, et al. Comparing outcomes of robotic and open inguinal lymph node dissection in patients with carcinoma of the penis. *J Urol* 2018;199:1518-25. <https://doi.org/10.1016/j.juro.2017.12.061>
19. Russell CM, Salami SS, Niemann A, et al. Minimally invasive inguinal lymphadenectomy in the management of penile carcinoma. *Urology* 2017;106:113-8. <https://doi.org/10.1016/j.urology.2017.04.022>
20. Michalik B, Engels S, Otterbach MC, et al. Bimodal inguinal sentinel lymph node imaging using a radiation-free fluorescent magnetic hybrid tracer in penile cancer patients. *Front Oncol* 2025;15:1523038. <https://doi.org/10.3389/fonc.2025.1523038>
21. Sharma P, Zargar-Shoshtari K, Pettaway CA, et al. Disparities in penile cancer. *Cancer Control* 2016;23:409-14. <https://doi.org/10.1177/107327481602300412>

CORRESPONDENCE: Dr. Murali K. Ankem, Department of Urology, University of Louisville School of Medicine, Louisville, KY, United States; murali.ankem@louisville.edu